Hybrid or Mixed Marketing Authorisation Application in the European Union

March 31, 2022
  • Drug Registration
  • Lifecycle Management
image_pdfPDF

In this white paper you will learn:

 

  • Basic EU legislation for medicinal products
  • Legal basis of the application in the EU
  • Hybrid applications
  • How to present your Hybrid application
  • Timetable for Hybrid applications under Article 10(3) of Directive 2001/83/EC
  • Post authorisation
  • Conclusion, Abbreviations & Bibliography

Register to download the White paper

    By sending this form, I agree that my personal data will be saved and processed according to data protection regulations and will be used only for commercial and marketing purposes only.

    Learn more


    BlueReg undertakes to comply with the regulations in force applicable to the processing of personal data and, in particular, Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 applicable as from 25 May 2018 (hereinafter, "the General Data Protection Regulations" or GPDR) and the national laws resulting therefrom.
    Any inquiries, correction or declaration of event related to personal data processed should be sent to: GDPR data request

    GDPR data request

    Thank you for your interest in BlueReg

    The file will be sent to you by email.

    Download your White paper